Speakers

Jane Davies is Professor of Paediatric Respirology & Experimental Medicine at the National Heart and Lung Institute, Imperial College London, in England and is a National Institute of Health Research Senior Investigator. She serves as Honorary Consultant in Paediatric Respiratory Medicine, Royal Brompton & Harefield NHS Foundation Trust, one of the largest CF clinics in Europe. Her main areas of research interest are cystic fibrosis chronic lung infection and clinical trial design. She has been global lead investigator on a large number of international trials of CFTR modulator drugs, including in children and infants and a member of the Strategy Group of the UK CF Gene Therapy Consortium. To support paediatric studies, she established the Lung Clearance Core Facility on behalf of the European CF Society, standardizing this more sensitive pulmonary outcome measure. She is currently Vice-President of the ECFS.

Ali Hariri, M.D., is Eloxx’s Chief Medical Officer, responsible for overseeing clinical development efforts for the company’s promising pipeline of therapies to treat rare diseases. Prior to joining Eloxx, Dr. Hariri served as Senior Global Project Head in Rare Disease Clinical Development at Sanofi-Genzyme where he oversaw key functions responsible for advancing a number of investigational therapies along with approval of supplemental indications for on-market therapies.

Prior to his role as Global Project Head at Sanofi-Genzyme, Dr. Hariri held several positions of increasing responsibility with expertise across a range of therapeutic areas including renal and immunology. Before joining Sanofi, Dr. Hariri held clinical development and medical affairs roles at Ionis and Takeda coordinating publication planning and health economics research. Dr. Hariri was also a practicing nephrologist.

Dr. Hariri earned his M.D. from the University of California San Diego School of Medicine, and his Bachelor of Science degree in biochemistry from California State University. He completed his residency at Case Western Reserve and a fellowship at Yale University School of Medicine. He served as faculty in the section of nephrology at Yale.

John Sheridan is the Director of Research at the Cystic Fibrosis Foundation where he is focused on advancing basic science and translational research to develop nucleic acid therapies that could lead to a one-time cure for CF.  Additionally, he oversees the Epithelial Stem Cell Consortium that is charged with characterizing the airway epithelial stem cell populations, optimizing induced pluripotent stem cell protocols, and developing stem cell engraftment models to advance genetic and cell-based therapies for CF.

Prior to joining the Cystic Fibrosis Foundation, John worked at the National Heart, Lung, and Blood Institute as a Program Director where he managed the cystic fibrosis research portfolio and co-developed the NIH Somatic Cell Genome Editing Program.  John received his Ph.D. in cell and molecular physiology from the University of North Carolina at Chapel Hill where his research focused on the mechanisms associated with regulating airway hydration.

Medical Director, Clinical Research Services
President-Elect, Medical Staff
Co-Director, Adult Cystic Fibrosis Program
CF Therapeutics Development Network Center Director
Professor (tenured), Departments of Medicine and Pediatrics
The Tuchman Family Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health

She has been site primary investigator on more than 45 clinical studies, and global site investigator on 3 clinical trials. She is an elected member of the American Society for Clinical Investigation (2020). Her investigator initiated research focuses on the development and evaluation of novel therapies for the treatment of CF, and on the unique health needs of women with CF. She is also investigating the etiology and treatment of bronchiectasis in non-human primates.

She serves on numerous local and national committees including as an advisor to the Cystic Fibrosis Foundation’s (CFF) Board of Trustees, on the CFF’s Clinical Research Advisory Board, the CF TDN’s Clinical Research Executive Committee and as Chair of the CF TDN’s Women’s Health Research Working Group. She is an Associate Editor for the Journal of Cystic Fibrosis. She serves on the American Thoracic Society (ATS) Scientific Advisory and Clinical Problems Programming Committee (Chair 2020-2021). She has co-chaired numerous sessions and given invited lectures at the ATS International Conference, and the North American, European and Australian CF Conferences, as well as at regional CF and pulmonary conferences and national and international veterinary conferences. She is an active member of the Colorado Chapter CF Board.  

Dr. Taylor-Cousar is a tenured professor of adult and pediatric pulmonary medicine at National Jewish Health (NJH), where she serves as the Medical Director of Clinical Research Services, President-elect of the medical staff, and is co-director of the Adult CF Program and Director of the CF Therapeutics Development Network (TDN) center.  She received her undergraduate degree in human biology from Stanford University in 1993, and completed her doctorate in medicine in 1998, combined residency in internal medicine and pediatrics in 2002, and her combined fellowship in adult and pediatric pulmonary medicine in 2006 at Duke University Medical Center. She obtained her Master of Clinical Science from the University of Colorado in 2015.